OBCK Ottobock SE & Co. KGaA
Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. The company is involved in identification, development, manufacturing, sales, and marketing of prosthetics, neuro-orthotics, and digital solutions; prostheses for the upper and lower extremities; mechanical prostheses and technologically sophisticated microprocessor-controlled; prosthetic knee joints and feet; arm and hand prostheses; and myoelectrical prostheses activities, as well as socket technologies, including liners, intelligent adaptors, and cosmetic components. It also provides fitting solutions for neurological indications; microprocessor-controlled orthotics, such as the C-Brace; and electrical muscle-activating stimulators, including exopulse suit and conventional orthotics; planning and equipping of patient care clinics; solutions for back, shoulder, neck, and wrist; customized orthopedic treatment and rehabilitation solutions; manual and power wheel chair; and standing aids and cushions, as well as care for amputees, including peripheral artery disease, traumatic limb loss, cancer, infections, congenital limb deficiencies, etc; and neurological etiologies, including stroke, multiple sclerosis, cerebral palsy/spinal cord injury, etc. In addition, the company leases out products, including wheelchairs and microprocessor-controlled knee joints. Ottobock SE & Co. was formerly known as Otto Bock HealthCare GmbH and changed its name to Ottobock SE & Co. KGaA in April 2018. The company was founded in 1919 and is based in Duderstadt, Germany. Ottobock SE & Co. KGaA operates as a subsidiary of Näder Upside 2 Vermögensverwaltungs GmbH.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Ottobock (ETR: OBCK)
›
Ottobock (ETR: OBCK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 9,455 employees.
The shares were at 37.70 EUR on 20 November 2026, down 45.8% over 52 weeks. Its 52-week range is 37.50 EUR to 76.35 EUR, and it trades at the bottom of that range.
At a market capitalisation of 2.41B EUR, it trades at 18.6 times trailing earnings and 10.6 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 62% for OBCK. It pays a dividend yielding 2.57% (it pays out 42% of its earnings), against a median of 0.92% among the dividend payers in that peer group.
Ottobock reports return on equity of 23.1%, an operating margin of 18.7% and revenue up 8.8% year over year.
Its debt exceeds its cash by 1.15B EUR, a debt-to-equity ratio of 2.69. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 72.25 EUR is 91.6% above the current price. The next earnings report is expected on 11 March 2027.